Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 15/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.48 |
| ▸ | CDK9 | P50750 | 12/20 | 0.48 |
| ▸ | CCNH | P51946 | 10/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.48 |
| ▸ | CCNK | O75909 | 7/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746692 | 1.00 | CDK7 (0.48) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20191043 | 1.00 | CDK7 (0.48) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20209310 | 0.91 | CDK7 (0.53) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20190962 | 0.91 | CDK7 (0.53) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20209562 | 0.90 | CDK7 (0.51) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20209673 | 0.89 | CDK7 (0.49) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL17688386 | 0.88 | CDK7 (0.55) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL18047281 | 0.87 | CDK7 (0.46) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL16654840 | 0.86 | CDK7 (0.53) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL16654926 | 0.85 | CDK7 (0.45) | CDK7CCNT1CDK9CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNT1 39/4885CDK9 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.